ATE330620T1 - Verwendung von midkin oder von anti-midkin antikörper - Google Patents

Verwendung von midkin oder von anti-midkin antikörper

Info

Publication number
ATE330620T1
ATE330620T1 AT98931102T AT98931102T ATE330620T1 AT E330620 T1 ATE330620 T1 AT E330620T1 AT 98931102 T AT98931102 T AT 98931102T AT 98931102 T AT98931102 T AT 98931102T AT E330620 T1 ATE330620 T1 AT E330620T1
Authority
AT
Austria
Prior art keywords
midkin
antibodies
midkine
inducible
heparin
Prior art date
Application number
AT98931102T
Other languages
English (en)
Inventor
Takashi Muramatsu
Tohru Takada
Kazuhiro Toriyama
Hisako Muramatsu
Original Assignee
Takashi Muramatsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takashi Muramatsu filed Critical Takashi Muramatsu
Application granted granted Critical
Publication of ATE330620T1 publication Critical patent/ATE330620T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT98931102T 1997-07-14 1998-07-14 Verwendung von midkin oder von anti-midkin antikörper ATE330620T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20532097 1997-07-14
JP20533297 1997-07-14

Publications (1)

Publication Number Publication Date
ATE330620T1 true ATE330620T1 (de) 2006-07-15

Family

ID=26515003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98931102T ATE330620T1 (de) 1997-07-14 1998-07-14 Verwendung von midkin oder von anti-midkin antikörper

Country Status (10)

Country Link
US (1) US7390491B2 (de)
EP (1) EP0998941B9 (de)
JP (1) JP2010215673A (de)
KR (1) KR100571010B1 (de)
CN (1) CN1287852C (de)
AT (1) ATE330620T1 (de)
AU (1) AU756279B2 (de)
CA (1) CA2296409C (de)
DE (1) DE69835016T2 (de)
WO (1) WO1999003493A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512200A (ja) * 1998-04-17 2002-04-23 アンジオジェニックス, インコーポレイテッド 治療的な脈管形成因子およびその使用方法
CN1222296C (zh) * 1998-08-24 2005-10-12 村松乔 动脉硬化和ptca术后再狭窄的预防剂/治疗剂
US20060259026A1 (en) * 2005-05-05 2006-11-16 Baylis Medical Company Inc. Electrosurgical treatment method and device
US8221758B2 (en) 2003-03-06 2012-07-17 Cellmid Limited Anti-midkine antibody for preventing post-laparotomy adhesions
JP4646070B2 (ja) * 2003-03-27 2011-03-09 メディカル セラピーズ リミテッド 関節炎関連遺伝子及びこれの関節炎検査等への利用
WO2007055378A1 (ja) * 2005-11-14 2007-05-18 Cell Signals Inc. 調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法
ES2397715T3 (es) 2006-11-14 2013-03-08 Ribomic Inc Aptámero contra midkina y uso del mismo
US9163081B2 (en) 2006-11-14 2015-10-20 Medical Therapies Limited Antibody recognizing C-domain of midkine
WO2010074218A1 (ja) * 2008-12-25 2010-07-01 株式会社イーベック 抗ヒトミッドカイン抗体
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
WO2012122590A1 (en) 2011-03-14 2012-09-20 Cellmid Limited Antibody recognizing n-domain of midkine
AU2013297478B2 (en) 2012-07-30 2018-12-20 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody against human midkine
KR101985300B1 (ko) * 2016-07-19 2019-06-03 삼성전자주식회사 미드카인 저해제를 포함하는 뇌종양 치료 또는 예방용 약학 조성물
CN118304417B (zh) 2024-06-11 2024-08-09 四川大学华西医院 一种能够抑制mdk表达的物质在制备治疗ddh药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79254A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
US5206223A (en) * 1986-06-26 1993-04-27 Yeda Research And Development Co. Ltd. Method for inhibiting heparanase activity
US5210026A (en) * 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
EP0583360B1 (de) 1991-05-02 2002-05-22 Yeda Research And Development Co. Ltd. Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen
EP0535336A3 (en) * 1991-09-30 1993-05-19 American Cyanamid Company Mk protein as cell growth inhibitor
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
AU7205894A (en) * 1993-06-08 1995-01-03 Neogenix, Inc. Purified natural and synthetic compounds for the treatment of osteoarthritis
DE69621528T2 (de) 1995-02-07 2003-01-16 Shiseido Co. Ltd., Tokio/Tokyo Anti-inflamatorische agenzien
JPH08277224A (ja) * 1995-02-07 1996-10-22 Shiseido Co Ltd 抗炎症剤
US5629284A (en) * 1995-07-24 1997-05-13 Meiji Milk Products Co., Ltd. Method for treating retinal diseases
JPH0995454A (ja) * 1995-10-02 1997-04-08 Meiji Milk Prod Co Ltd 抗潰瘍組成物
ATE299030T1 (de) * 1996-07-10 2005-07-15 Meiji Dairies Corp Verwendung von proteinen aus der mk familie als hämatopoietischer faktor

Also Published As

Publication number Publication date
EP0998941A4 (de) 2004-05-12
WO1999003493A1 (en) 1999-01-28
CA2296409A1 (en) 1999-01-28
JP2010215673A (ja) 2010-09-30
CA2296409C (en) 2010-05-18
CN1287852C (zh) 2006-12-06
DE69835016T2 (de) 2007-06-28
EP0998941B1 (de) 2006-06-21
EP0998941B9 (de) 2007-03-14
KR20010021814A (ko) 2001-03-15
US7390491B2 (en) 2008-06-24
CN1306435A (zh) 2001-08-01
AU8131098A (en) 1999-02-10
US20030072739A1 (en) 2003-04-17
KR100571010B1 (ko) 2006-04-13
EP0998941A1 (de) 2000-05-10
AU756279B2 (en) 2003-01-09
DE69835016D1 (de) 2006-08-03

Similar Documents

Publication Publication Date Title
DE69835016D1 (de) Verwendung von midkin oder von anti-midkin antikörper
DE3667378D1 (de) Verwendung von n-(4-phenoxy-2,6-diisopropylphenyl)-n'-tert.butylthioharnstoff zur bekaempfung von weissen fliegen.
DE69008423D1 (de) Dynamische Fixierung von Schweinsaortaklappen.
EP0963197A4 (de) Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten
ATE286510T1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
DE3687069D1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
ATE245442T1 (de) Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
FI920992L (fi) Foerfarande foer framstaellning av i industriell skala av ett standardiserat koncentrat av human von willebrand-faktor, vilket har synnerligen hoeg renhet och aer laempligt foer terapeutisk anvaendning
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
DE3788984D1 (de) Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom.
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
ATE103932T1 (de) Fusionsprotein bestehend aus gm-csf und il-3.
DE69001839D1 (de) 1-hydroxyvitamin d2-epimer und dessen derivate.
DE3774858D1 (de) Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeuren und deren verwendung als collagenase-inhibitoren.
DE3680000D1 (de) Stabilisierte aktive formen von vitamin-d3.
EP0209543A4 (de) Peptidfragmente menschlicher apolipoproteine, typspezifische antikörper und verwendungsverfahren.
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
ATE208042T1 (de) Hapten-analoge zur verwendung in immunoassays
DE69319576D1 (de) Verwendung von Furanonen wie Duftstoffe
DE69414194D1 (de) Aminosäurederivate und ihre Verwendung als Enkephalinase-Inhibitoren
ATE227557T1 (de) Verwendung von zahnpflegemitteln enthaltend bovines kolostrum
ATE222896T1 (de) Substituierte thiazoline und ihre verwendung zur bekämpfung von tierischen schädlingen
ATE493951T1 (de) Kortikalknochenimplantat für wirbelfusion nach smith-robinson
DE3751362D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
DE3871712D1 (de) Suspensionen und verwendung dieser suspensionen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties